Insight Molecular Diagnostics's total assets for Q1 2026 were $40.43M, an increase of 56.96% from the previous quarter. IMDX total liabilities were $51.12M for the fiscal quarter, a -10.66% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.